THE UNITED States' Eli Lilly expects to introduce three new experimental drugs next year, despite being investigated by the US Food and Drug Administration. The company, which has been cited for more than 200 manufacturing deficiencies this year and has so far invested more than US$50 million to improve its performance, foresees regulatory approval next year to sell the new drugs. Lilly Chief Executive Officer Sidney Taurel told investors meeting in New York earlier this month (Nov.) that he expects osteoporosis-fighter Forteo to be ...

Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.